Germany · Delayed Price · Currency is EUR D. Western Therapeutics Institute Company Description
D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs.
The company offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; DWR-2206, a regenerative medicine cell-product for bullous keratopathy; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining.
It is also developing DW-5LBT, a lidocaine patch for neuropathic pain after shingles; K-321 to treat fuch endothelial corneal dystrophy which is in Phase III clinical trials; and H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension.
The company was founded in 1999 and is headquartered in Nagoya, Japan.
| Country | Japan |
| Founded | 1999 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 21 |
| CEO | Yuichi Hidaka |
Contact Details
Address: CK21 Hirokoujifushimi Bldg. Nagoya, 460-0003 Japan | |
| Phone | 81 5 2218 8785 |
| Website | dwti.co.jp |
Stock Details
| Ticker Symbol | 6DW |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | JPY |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Yuichi Hidaka | Chief Executive Officer |
| Sayako Matsubara | Chief Financial Officer |